Nuclear-anchored FGFR regulates cell proliferation and cisplatin resistance in pancreatic ductal adenocarcinoma

Author:

Yue Zhi-qiang1

Affiliation:

1. Bosiyan Biotechnology (Suzhou) Co., Ltd.

Abstract

Abstract Background In natural physiological conditions, FGF is a pleiotropic growth factor with multiple bio-activities and FGF/FGFR system has many important biological functions and roles. Interestingly, more and more evidences show that FGF/FGFR system plays an important role in the occurrence and development of pancreatic ductal adenocarcinoma. Methods In our study, we explored the cellular characteristics of FGF/FGFR system in pancreatic ductal adenocarcinoma cells. In addition, we also investigated the relationship between nuclear localized FGF/FGFR and cisplatin resistance. A series of experimental techniques including indirect immunofluorescence, Western-blot and ELISA were used to analyze the cellular characteristics of FGF/FGFR. We systematically assessed the cell behavior of IGF-1/IGF-1R in the Pancreatic ductal adenocarcinoma cell model. Results We have three main findings: First, we found that IGF-1R could transport into the cell nuclei of Pancreatic ductal carcinoma cell, and the nuclear-localized FGF/FGFR was closely related to the proliferation of Pancreatic ductal carcinoma cells. Additionally, we also found that the nuclear-localized FGF/FGFR might be closely associated with cisplatin resistance in pancreatic ductal adenocarcinoma, this may be a potential mechanism of cisplatin resistance; Secondly, we found that the nuclear-localized FGF/FGFR showed a positive correlation with the intensity of AKT signaling. Conclusions Taken together, this work lays the foundation for further research on the relationship between the nuclear FGF/FGFR and the pancreatic ductal adenocarcinoma development or cisplatin resistance in pancreatic ductal adenocarcinoma.

Publisher

Research Square Platform LLC

Reference29 articles.

1. The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives;Wang S;Signal Transduct Target Ther,2021

2. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Ducreux M;Ann Oncol,2015

3. Cancer statistics, 2019;Siegel RL;CA Cancer J Clin.,2019

4. Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma;Kopp JL;Cancer Cell.,2012

5. Sarvepalli D, Rashid MU, Rahman AU, Ullah W, Hussain I, Hasan B, Jehanzeb S, Khan AK, Jain AG, Khetpal N et al. Gemcitabine: A Review of Chemoresistance in Pancreatic Cancer. Crit Rev Oncog. 2019, 24:199–212.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3